Question
give a general reaction of asymmetric 1, 2-aminohydroxylation of alkenes using (DHQ)2-PHAL AD catalyst in the presence of (TsNCINa). Also give various nitrene equivalents which are frequently as reagents in this reaction.
Answer :
Word Count : 239
_________ ___ _____ _______ ______ _____ ____ _________ _____ _________ ____.
_____ ___ ______ _______ _______ ______ ______ ____ ________ _______ ____ _____.
_____ __________ __________ ________ ______ _____ _____ _____ __________ _____ ___ ____.
________ __________ ____ _____ _____ _______.
__________ _________ _____ ___ _________.
__________ ________ ______ _______ ___ ___ ____ ___ _________ ______ ____.
________ __________ ______ ___ ______ ___ ______ ___ ___ _________ ______.
____ _________ ____ ___ _____.
_____ ________ __________ _____ _____ ___ _____.
______ __________ ________ _______ _____ ______ ___ ______ _____ _______ ___ ______.
____ _________ _________ ______ _________.
__________ _________ __________ _______ _____ ________ ______ ___ ________ _____ _________.
______ _____ _________ ______ ______ _______ ________ _______.
__________ __________ ____ ___ ______ ____ ______ _____ _____ ________ _____ ________.
________ __________ ___ ____ ______ _______ ___ _____ _______ _________.
____ ______ ___.
Skip in 10
The asymmetric 1,2-aminohydroxylation of alkenes is an important method for the preparation of vicinal amino alcohols with high enantioselectivity. A general reaction involves the use of a chiral ligand such as (DHQ)₂-PHAL in combination with an oxidant in the presence of nitrene precursors. In the typical protocol, an alkene substrate reacts with a nitrene equivalent like TsN–X (where X is a leaving group) under the catalysis of the (DHQ)₂-PHAL complex to generate a chiral amino alcohol. In the presence of (TsNCINa), which serves as a source of the tosyl nitrene, the
_________ _________ ______ _______ _____ ________ ______._________ ___ _____ _______ ______ _____ ____ _________ _____ _________ ____.
_____ ___ ______ _______ _______ ______ ______ ____ ________ _______ ____ _____.
_____ __________ __________ ________ ______ _____ _____ _____ __________ _____ ___ ____.
________ __________ ____ _____ _____ _______.
__________ _________ _____ ___ _________.
__________ ________ ______ _______ ___ ___ ____ ___ _________ ______ ____.
________ __________ ______ ___ ______ ___ ______ ___ ___ _________ ______.
____ _________ ____ ___ _____.
_____ ________ __________ _____ _____ ___ _____.
______ __________ ________ _______ _____ ______ ___ ______ _____ _______ ___ ______.
____ _________ _________ ______ _________.
__________ _________ __________ _______ _____ ________ ______ ___ ________ _____ _________.
______ _____ _________ ______ ______ _______ ________ _______.
__________ __________ ____ ___ ______ ____ ______ _____ _____ ________ _____ ________.
________ __________ ___ ____ ______ _______ ___ _____ _______ _________.
____ ______ ___.
IGNOU ACADEMY
Your IGNOU journey, made easier.
- Solved Assignments
- Study Notes
- Guess Papers
- Question Papers
Continue Reading — It's Free
Sign in with Google to unlock more of this answer.
✓ Free access
✓ Unlock up to 60% of the answer
✓ No payment required
✓ Unlock up to 60% of the answer
✓ No payment required
Quick Google sign-in. No separate registration form.
Related Questions
Pyrizino [2,3-d] pyridazine
) 3-Methylazacyclohexane
Maquene synthesis
Give any two examples of synthetic antimalarial drugs with structure wherein a quinoline moiety is present.
Explain using suitable diagram the mechanism of catalytic hydrogenation of an alkene.
How many signals will appear in the 1H-NMR of the following compounds?
Draw the products of the following:
(i) Reduction of quinoline with different reagents.
(ii) Oxidative cleavage of quinoline
(iii) Bromination of quinoline